CONBA(SH:600572) Ge Long Hui·2026-02-12 10:37Core Viewpoint - Company subsidiaries participated in the national organized procurement for the continuation of drug agreements, with 11 products selected for procurement, indicating a stable revenue stream for the company in the coming years [1][2] Group 1: Procurement Details - The company’s subsidiaries, Hangzhou Kang En Bei Pharmaceutical Co., Ltd. and Zhejiang Jinhua Kang En Bei Biopharmaceutical Co., Ltd., submitted applications for the national organized procurement continuation [1] - The selected drugs include sustained-release capsules of Tamsulosin Hydrochloride, injectable Piperacillin Sodium and Tazobactam Sodium, and enteric-coated Pantoprazole Sodium tablets among others [1][2] - The expected sales revenue from the selected drugs for 2024 is approximately 385.29 million yuan, accounting for 5.91% of the company's total revenue for that year [1] Group 2: Financial Impact - For the first three quarters of 2025, the total expected sales revenue from the selected drugs is about 296.15 million yuan, representing 5.95% of the company's revenue for that period [1] - The procurement results are expected to be implemented by the end of March 2026, with medical institutions prioritizing the use of selected drugs [2] - The prices of the selected drugs are expected to remain stable or decrease, with procurement quotes maintaining stability compared to the average sales prices in 2025 [2]